Phase 2 N=34 Biological Effects of Weight Loss In Older, Obese Women
Obesity · Sarcopenia
Primary: Performance on the 400 Meter Walk — 0.16; 0.02 meters per second — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Breast Cancer
Primary: Number of Participants With Complete Pathologic Response. — 13 participants
Phase 2 N=19 Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
Primary: Number of Patients With Confirmed Responses — 2; 0 participants
Phase 2 N=151 Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Cystic Fibrosis (CF)
Primary: Change in P. Aeruginosa Density — 0.23; -0.31; -0.31; -0.73 log10 CFU/g sputum — p=0.0014
Phase 2 N=42 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas
Ewing's Sarcoma · Rhabdomyosarcoma
Primary: Number of Participants With an Immune Response to Tumor-specific and Non-tumor Specific Peptides During a Period of Immune Reconstitution — 9; 23 Participants
Phase 2 N=186 Vigabatrin for Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment. — 7; 5 participants
Phase 2 N=37 RO4929097 in Treating Patients With Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Number of Participants With Objective Radiographic Response (ORR) — 0 participants
Phase 2 N=157 Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo — 18.1; 16.1 weeks — p=0.148
Phase 2 N=163 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
Multiple Myeloma
Primary: Overall Best Confirmed Response — 101; 6 number of participants
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 2 N=103 Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386
Pain
Primary: Sum of Pain Intensity Difference in Percent (SPID%) — 35.5; 171.8; -7.5 percentage of pain intensity change * h
Phase 2 N=35 Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
Primary: Objective PSA Response Rate (Number of Patients With a PSA Response) — 17; 18 participants
Phase 2 N=66 ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
Non Small Cell Lung Cancer · Lung Cancer
Primary: Time to Death — 193; 146 Days
Phase 2 N=172 A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
Metastatic Colorectal Cancer
Primary: Progression Free Survival — 10.23; 8.85; 8.32 Months
Phase 2 N=1,518 Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
Asthma
Primary: Time to First Serious Asthma Exacerbation — 13.3; 13.4 months